IL-2 plus | IL-2 minus | P | |
---|---|---|---|
(N=149) | (N=83) | ||
Immunosuppression at 10 weeks | |||
CsA | 99 (67%) | 60 (77%) | ns |
Tacrolimus | 31 (21%) | 10 (13%) | ns |
mTOR inhibitor | 14 (10%) | 9 (12%) | ns |
CsA dose (mg/day) | 250.5 ± 73.5 | 255.4 ± 87.8 | ns |
CsA C0 concentration | 151.4 ± 56.5 | 183.3 ± 85.6 | 0.01 |
Tacrolimus dose (mg/day) | 5.65 ± 2.95 | 8.70 ± 4.64 | ns |
Tacrolimus concentration | 7.3 ± 2.1 | 9.2 ± 2.3 | ns |
Prednisolone dose (mg/day) | 12,4 ± 5.6 | 13.6 ± 5.6 | ns |
MMF (mg/day) | 1678.1 ± 402.9 | 1750.0 ± 619.9 | ns |
Outcome | |||
Delayed graft function | 53 (36%) | 29 (35%) | ns |
Acute rejection 90 days post transplant | 29 (20%) | 34 (41%) | 0.001 |
Acute rejection 180 days post transplant | 38 (26%) | 35 (42%) | 0.01 |
Steroid-resistant rejection (biopsy proven) | 5 (3%) | 18 (22%) | < 0.001 |
C4D positive biopsy | 4 (5%) | 4 (3%) | ns |
Cause of graft loss | |||
Death with functioning graft | 32 (22%) | 24 (29%) | ns |
Primary non-function | 0 | 6 (7%) | 0.002 |
Primary vascular thrombosis | 3 (2%) | 2 (2%) | ns |
Rejection | 5 (3%) | 10 (12%) | 0.02 |
Recurrent primary disease | 0 | 1 (1%) | ns |
Urological complications | 1 (1%) | 0 | ns |
De novo glomerulonephritis | 1 (1%) | 0 | ns |
Insufficient graft function | 0 | 2 (2%) | ns |
Not specified | 2 (1%) | 2 (2%) | ns |